Clinical Trial Update: OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating OPT-80 for Clostridium difficile-associated diarrhea has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile-associated Diarrhea

Drugs mentioned

• OPT-80 (fidaxomicin)

Snippet

Sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Diarrhea | Phase 2 | Status: COMPLETED